These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Hepatitis C virus (HCV), anti-HCV and non-A, non-B hepatitis].
    Author: Grob PJ, Joller-Jemelka HJ.
    Journal: Schweiz Med Wochenschr; 1990 Feb 03; 120(5):117-24. PubMed ID: 2106158.
    Abstract:
    Our data on 559 serum samples are discussed in the light of the present knowledge on hepatitis C virus (HCV). This newly discovered virus is thought to be the main cause of the bloodborne non-A, non-B hepatitis. HCV is a single-stranded, encapsulated RNS virus. Presently one antibody, anti-HCV, is detectable, which is directed against a nonstructural viral component. This antibody appears only weeks to months after infection or onset of the disease. Within 6-9 months 60-80% of the patients with resolving non-A, non-B hepatitis become positive, with the anti-HCV usually disappearing after 1-5 years. Patients with chronic infections are positive in 70-90% of cases, with the antibody usually persisting over decades. The presence of anti-HCV offers no clue as to whether there is an ongoing or past infection and does not serve to judge infectivity or immunity. 0.34% of the blood donors in Switzerland are anti-HCV positive, with 1.3% in Southern Italy and 0.6-0.8% in Northern Italy, Great Britain, France and Germany. Anti-HCV prevalence is high in hemophiliacs (59-97%), i.v. drug users (48-92%) hemodialysis patients and polytransfused individuals (3-23%), homosexuals and promiscuous heterosexuals (1-40%) as well as in patients with non-B hepatoma (62-80%) or with alcoholic cirrhosis (27-52%). Our own data show anti-HCV in 45% of i.v. drug users, 7% of homosexuals, 13% of patients under hemodialysis or with renal transplants, and in 60% of patients with chronic non-A, non-B hepatitis.
    [Abstract] [Full Text] [Related] [New Search]